ARDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aridis Pharmaceuticals's share price for the quarter that ended in Sep. 2023 was $0.1021. Aridis Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 44.57 Mil. Therefore, Aridis Pharmaceuticals's market cap for the quarter that ended in Sep. 2023 was $4.55 Mil.
Aridis Pharmaceuticals's quarterly market cap declined from Mar. 2023 ($11.33 Mil) to Jun. 2023 ($7.93 Mil) and declined from Jun. 2023 ($7.93 Mil) to Sep. 2023 ($4.55 Mil).
Aridis Pharmaceuticals's annual market cap declined from Dec. 2020 ($61.10 Mil) to Dec. 2021 ($41.24 Mil) and declined from Dec. 2021 ($41.24 Mil) to Dec. 2022 ($31.90 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aridis Pharmaceuticals's Enterprise Value for Today is $7.44 Mil.
The historical data trend for Aridis Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Market Cap | Get a 7-Day Free Trial | 89.88 | 39.69 | 61.10 | 41.24 | 31.90 |
Aridis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Market Cap | Get a 7-Day Free Trial | 16.46 | 31.90 | 11.33 | 7.93 | 4.55 |
For the Biotechnology subindustry, Aridis Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aridis Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
Market Cap (A: Dec. 2022 ) | = | Share Price (A: Dec. 2022 ) | * | Shares Outstanding (EOP) (A: Dec. 2022 ) |
= | $1.18 | * | 27.0335 | |
= | $31.90 |
Aridis Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2023 is calculated as
Market Cap (Q: Sep. 2023 ) | = | Share Price (Q: Sep. 2023 ) | * | Shares Outstanding (EOP) (Q: Sep. 2023 ) |
= | $0.1021 | * | 44.574 | |
= | $4.55 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals (OTCPK:ARDS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Fibrosis Foundation Cystic | 10 percent owner | 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814 |
Hasan Jafri | officer: Chief Medical Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Vu Truong | director, 10 percent owner, officer: CEO, CSO, Director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Eric Patzer | director, 10 percent owner | 5941 OPTICAL CT., SAN JOSE CA 95138 |
John F Hamilton | director | 1360 O'BRIEN DR, MENLO PARK CA 94025 |
Michael Adrian Nazak | officer: Chief Financial Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Susan Richards Windham-bannister | director | 78 BLANCHARD ROAD, BURLINGTON MA 01803 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Fred Kurland | officer: Chief Financial Officer | C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Robert R Ruffolo | director | |
Shawn Lu | director | C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326 |
Robert K. Coughlin | director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Craig S Gibbs | director | C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
From GuruFocus
By PRNewswire PRNewswire • 06-25-2022
By Value_Insider Value_Insider • 12-12-2022
By ACCESSWIRE ACCESSWIRE • 06-30-2022
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 03-31-2023
By Stock market mentor Stock market mentor • 01-17-2023
By Value_Insider Value_Insider • 12-05-2022
By Tiesvg Tiesvg • 12-28-2022
By sperokesalga sperokesalga • 05-31-2023
By PRNewswire PRNewswire • 06-23-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.